The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 338:548 February 19, 1998 Number 8
NextNext

More about Thrombotic Thrombocytopenic Purpura

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
To the Editor: Kupfer and Tessler (Oct. 23 issue)1 report a possible association of ticlopidine with fatal thrombotic thrombocytopenic purpura in two patients, but they imply that platelet transfusion is standard therapy for thrombotic thrombocytopenic purpura. In fact, the report illustrates the potential hazard of platelet transfusion for the condition. Platelet transfusions have been temporally associated with severe exacerbations of thrombotic thrombocytopenic purpura,2,3 including rapid deterioration and death, as occurred in one of the women described by Kupfer and Tessler, who died within six hours after platelet transfusion. The most likely mechanism for the adverse effect appears to be exacerbation . . . [Full Text of this Article]

References


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.